AiPD: Autoinhibited Protein Database

P31371

Gene name	FGF9
Protein name	Fibroblast growth factor 9
Names	FGF-9 , Glia-activating factor , GAF , Heparin-binding growth factor 9 , HBGF-9
Species	Homo sapiens (Human)
KEGG Pathway	hsa:2254
EC number
Protein Class	FIBROBLAST GROWTH FACTOR (PTHR11486)

Descriptions

The mammalian fibroblast growth factor (FGF)1 family contains at least 22 distinct polypeptides (FGF1–FGF22) that are expressed in a specific spatial and temporal pattern. FGF9 was originally described as a glia-activating factor and is expressed in the nervous system as a potent mitogen for glia cells. FGF9 adopts a beta-trefoil fold similar to other FGFs, but the N- and C-terminal regions outside the beta-trefoil core are ordered (typical FGFs have disordered tails) and involved in reversible dimerization. Due to the dimerization, a significant surface area is buried in the dimer interface that occludes a major receptor binding site of FGF9 within the beta-trefoil core.

Autoinhibitory domains (AIDs)

Target domain	63-190 (beta-trefoil core)
Relief mechanism
Assay	Structural analysis

AID

53-60 (N-terminal helix)

Target domain

63-190 (beta-trefoil core)

Relief mechanism

Assay

Structural analysis

Target domain	63-190 (beta-trefoil core)
Relief mechanism
Assay	Structural analysis

AID

200-203 (C-terminal helix)

Target domain

63-190 (beta-trefoil core)

Relief mechanism

Assay

Structural analysis

Accessory elements

No accessory elements

References

Plotnikov AN et al. (2001) "Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition", The Journal of biological chemistry, 276, 4322-9

Autoinhibited structure

Activated structure

4 structures for P31371

Entry ID	Method	Resolution	Chain	Position	Source
1G82	X-ray	260 A	A/B/C/D	49-208	PDB
1IHK	X-ray	220 A	A	35-208	PDB
5W59	X-ray	250 A	A	35-208	PDB
AF-P31371-F1	Predicted				AlphaFoldDB

160 variants for P31371

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
CA387674103 rs1555223925 RCV000513493	62	R>G	Multiple synostoses syndrome 3 Multiple synostoses syndrome 3 (syns3) [ClinVar, Ensembl]	Yes	ClinGen ClinVar Ensembl dbSNP
RCV000393748 CA6909464 RCV001859866 rs776951218	95	L>V	Multiple synostoses syndrome 3 [ClinVar]	Yes	ClinGen ClinVar ExAC TOPMed dbSNP gnomAD
CA119846 RCV000009242 VAR_063254 rs121918322	99	S>N	Multiple synostoses syndrome 3 Multiple synostoses syndrome 3 (syns3) SYNS3; expressed and secreted as efficiently as wild-type; however it induces compromised chondrocyte proliferation and differentiation accompanied by enhanced osteogenic differentiation and matrix mineralization of bone marrow-derived mesenchymal stem cells [ClinVar, Ensembl, UniProt]	Yes	ClinGen ClinVar UniProt Ensembl dbSNP
rs1254230677	2	A>V		No	gnomAD
rs1871777564	3	P>L		No	TOPMed
rs1480995733	3	P>S		No	TOPMed
rs1162900422	6	E>D		No	TOPMed gnomAD
rs868605138	6	E>K		No	Ensembl
rs1234728690 COSM1207082	7	V>A	large_intestine [Cosmic]	No	cosmic curated TOPMed gnomAD
COSM3417425	11	F>L	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
RCV002019638 rs182718810	13	V>E		No	ClinVar 1000Genomes TOPMed dbSNP gnomAD
rs182718810	13	V>G		No	1000Genomes TOPMed gnomAD
rs145436564 RCV000922891	14	Q>H		No	ClinVar 1000Genomes ESP ExAC TOPMed dbSNP gnomAD
rs1430778022	14	Q>L		No	gnomAD
COSM4046471	14	Q>R	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs997306736	15	D>H		No	TOPMed gnomAD
TCGA novel	15	D>N	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel rs1871778354	16	A>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Ensembl
rs1871778625	17	V>I		No	TOPMed
rs1212322820	18	P>L		No	gnomAD
rs774583506	18	P>S		No	ExAC TOPMed gnomAD
rs767912297	20	G>A		No	ExAC TOPMed gnomAD
rs1871779016	20	G>R		No	Ensembl
rs1426446815	23	P>S	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	Ensembl NCI-TCGA
rs1871779407	24	V>A		No	TOPMed
rs1277842781	25	L>F		No	gnomAD
rs750656784	25	L>V		No	ExAC gnomAD
RCV001970901 rs1871779721	26	P>R		No	ClinVar Ensembl dbSNP
rs759293888	26	P>S		No	ExAC TOPMed gnomAD
rs1187048373	27	V>A		No	gnomAD
rs1412420802	27	V>L		No	TOPMed gnomAD
rs1238303573	28	D>N		No	gnomAD
rs1871780186	30	P>L		No	Ensembl
rs576881958	30	P>S		No	1000Genomes ExAC TOPMed gnomAD
rs376187337	31	V>L		No	ESP ExAC TOPMed gnomAD
rs570227715	32	L>F		No	1000Genomes ExAC gnomAD
rs1871780623	34	S>G		No	gnomAD
rs1362488166	34	S>N		No	TOPMed
rs1373965286	35	D>G		No	TOPMed gnomAD
rs150678654	38	G>A		No	ESP
rs751136069	38	G>R		No	ExAC gnomAD
rs756744215	40	S>A		No	ExAC gnomAD
rs780871403	42	A>G		No	ExAC gnomAD
rs1565947231	44	G>AIRVH*		No	Ensembl
rs1301192320	45	L>F		No	TOPMed gnomAD
rs780484804	48	G>R		No	ExAC gnomAD
rs2138124932	49	P>L		No	Ensembl
COSM4826614	50	A>P	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1346570038	50	A>T		No	gnomAD
rs774988398	51	V>I		No	ExAC gnomAD
rs772251822	52	T>M		No	ExAC gnomAD
rs755561237	52	T>P		No	ExAC TOPMed gnomAD
rs755561237	52	T>S		No	ExAC TOPMed gnomAD
rs760974340	54	L>F		No	ExAC gnomAD
rs1871782573	55	D>H		No	Ensembl
rs1213378667	56	H>D		No	TOPMed
COSM5531254	56	H>Y	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs267603776	59	G>E		No	Ensembl
rs1871783472	65	Q>R		No	Ensembl
rs762649405	69	R>S		No	ExAC gnomAD
COSM4046472	70	T>A	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1258794930	70	T>S		No	TOPMed gnomAD
COSM4879051	74	L>S	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs751475837	76	I>V		No	ExAC gnomAD
rs756799366	78	P>A		No	ExAC TOPMed gnomAD
rs767042516	78	P>L		No	ExAC gnomAD
TCGA novel	78	P>S	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1226739190	79	N>D		No	gnomAD
rs749883098	79	N>S		No	ExAC
COSM4046473	80	G>D	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs755802170	80	G>S		No	ExAC gnomAD
COSM6138968	82	I>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1214948323	86	R>G		No	TOPMed gnomAD
rs749722061	88	D>A		No	ExAC gnomAD
rs779502534	88	D>H		No	ExAC
rs1210713262	89	H>N		No	gnomAD
rs755277615	89	H>P		No	ExAC gnomAD
rs779607710	91	R>G		No	ExAC gnomAD
VAR_020944 RCV000959093 rs12427696	94	I>V		No	ClinVar UniProt 1000Genomes ESP ExAC TOPMed dbSNP gnomAD
rs1352104938	100	I>M		No	gnomAD
rs1308480939	100	I>V		No	gnomAD
COSM6074453	101	A>E	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
COSM3467671	103	G>S	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
COSM275167	108	R>*	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
COSM223624 rs753255725	108	R>Q	Variant assessed as Somatic; MODERATE impact. skin breast [NCI-TCGA, Cosmic]	No	NCI-TCGA Cosmic cosmic curated NCI-TCGA gnomAD
rs774141078	110	V>M	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	ExAC NCI-TCGA gnomAD
rs1872033513	111	D>E		No	Ensembl
COSM3467672	113	G>E	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1872033637	114	L>P		No	Ensembl
rs1245671881	116	L>I		No	TOPMed gnomAD
rs2138133986	117	G>R		No	Ensembl
TCGA novel	121	K>R	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA
rs1872034052	123	E>K		No	TOPMed
rs773003683	124	L>M		No	ExAC TOPMed gnomAD
TCGA novel	125	Y>N	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs765842747	126	G>R		No	ExAC gnomAD
rs1198320298	127	S>A		No	gnomAD
COSM4878283	127	S>T	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
COSM1686195 rs1189091971	128	E>K	skin [Cosmic]	No	cosmic curated gnomAD
TCGA novel	129	K>N	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA
rs1379079857	130	L>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA TOPMed
rs1391997109	130	L>P		No	gnomAD
rs267603777	132	Q>*		No	ExAC TOPMed gnomAD
rs267603777	132	Q>E		No	ExAC TOPMed gnomAD
rs770847282	133	E>D		No	ExAC TOPMed gnomAD
rs200015821	134	C>S		No	ExAC gnomAD
rs1466682170	135	V>I		No	gnomAD
rs759113908	136	F>L		No	ExAC gnomAD
rs1338958021	136	F>L		No	gnomAD
COSM945978	137	R>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs765041263	140	F>L	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	ExAC NCI-TCGA TOPMed gnomAD
rs1010781871 COSM5132866	141	E>K	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic NCI-TCGA TOPMed gnomAD
COSM3417426	142	E>*	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
TCGA novel	144	W>*	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA
rs963305629	147	T>M		No	TOPMed gnomAD
rs751903634	149	S>L		No	ExAC gnomAD
COSM1322936	150	S>*	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1242434501	151	N>K		No	TOPMed gnomAD
rs750565955	152	L>V		No	ExAC gnomAD
rs143118647	155	H>Q		No	ESP ExAC TOPMed gnomAD
rs749546597	156	V>L		No	ExAC gnomAD
rs1208866316	158	T>S		No	gnomAD
rs1249806783	159	G>R		No	gnomAD
COSM469244	161	R>*	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs146697820	161	R>P		No	ESP ExAC TOPMed gnomAD
rs146697820	161	R>Q		No	ESP ExAC TOPMed gnomAD
rs746751637	167	N>S		No	ExAC gnomAD
rs746751637	167	N>T		No	ExAC gnomAD
rs1304374985	168	K>E		No	TOPMed gnomAD
rs267603778	169	D>N		No	Ensembl
rs1267713584	171	T>S		No	gnomAD
rs371548027	172	P>L		No	ESP
rs776618974	172	P>S		No	ExAC TOPMed gnomAD
COSM1706514	174	E>K	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1366332994	175	G>A		No	TOPMed
COSM136929	175	G>E	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs550814848	180	R>Q		No	1000Genomes ExAC gnomAD
rs763743837 COSM212219	180	R>W	breast [Cosmic]	No	cosmic curated ExAC TOPMed gnomAD
rs1424759069	181	H>N		No	Ensembl
rs762229622	182	Q>R		No	ExAC gnomAD
rs767964377	184	F>L		No	ExAC TOPMed gnomAD
rs1872538187	185	T>I		No	TOPMed
COSM2265921	188	L>Y	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs2138150227 RCV002225982	189	P>R		No	ClinVar Ensembl dbSNP
rs1872538346	192	V>A		No	TOPMed gnomAD
rs1872538875	195	D>E		No	TOPMed
rs755164853	195	D>G		No	ExAC gnomAD
rs369272027	195	D>N		No	ESP ExAC TOPMed gnomAD
rs369272027	195	D>Y		No	ESP ExAC TOPMed gnomAD
rs1872539185	200	L>V		No	TOPMed gnomAD
rs1357445252	201	Y>C		No	TOPMed
rs1565954891	202	K>M		No	Ensembl
rs1565954891	202	K>R		No	Ensembl
rs1220671836	203	D>A		No	gnomAD
rs868277032	203	D>N		No	Ensembl
TCGA novel	205	L>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1872540065	205	L>P		No	Ensembl
rs1489320468	206	S>G		No	gnomAD
rs1283814283	207	Q>R		No	TOPMed gnomAD
COSM4962730	208	S>R	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic

1 associated diseases with P31371

[MIM: 612961]: Multiple synostoses syndrome 3 (SYNS3)

A bone disease characterized by multiple progressive joint fusions that commonly involve proximal interphalangeal, tarsal-carpal, humeroradial and cervical spine joints. Additional features can include progressive conductive deafness and facial dysmorphism. . Note=The disease is caused by variants affecting the gene represented in this entry.

Without disease ID

A bone disease characterized by multiple progressive joint fusions that commonly involve proximal interphalangeal, tarsal-carpal, humeroradial and cervical spine joints. Additional features can include progressive conductive deafness and facial dysmorphism. . Note=The disease is caused by variants affecting the gene represented in this entry.

No regional properties for P31371

Type	Name	Position	InterPro Accession
No domain, repeats, and functional sites for P31371

Functions

		Description
EC Number
Subcellular Localization	Secreted
PANTHER Family	PTHR11486	FIBROBLAST GROWTH FACTOR
PANTHER Subfamily	PTHR11486:SF28	FIBROBLAST GROWTH FACTOR 9
PANTHER Protein Class	intercellular signal molecule growth factor
PANTHER Pathway Category	FGF signaling pathway FGF

3 GO annotations of cellular component

Name	Definition
cytoplasm	The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.
extracellular space	That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.

3 GO annotations of molecular function

Name	Definition
fibroblast growth factor receptor binding	Binding to a fibroblast growth factor receptor (FGFR).
growth factor activity	The function that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation.
heparin binding	Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues.

47 GO annotations of biological process

Name	Definition
activin receptor signaling pathway	The series of molecular signals initiated by an extracellular ligand binding to an activin receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.
angiogenesis	Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.
animal organ morphogenesis	Morphogenesis of an animal organ. An organ is defined as a tissue or set of tissues that work together to perform a specific function or functions. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.
canonical Wnt signaling pathway	The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes. In this pathway, the activated receptor signals via downstream effectors that result in the inhibition of beta-catenin phosphorylation, thereby preventing degradation of beta-catenin. Stabilized beta-catenin can then accumulate and travel to the nucleus to trigger changes in transcription of target genes.
cardiac muscle cell proliferation	The expansion of a cardiac muscle cell population by cell division.
cell differentiation	The cellular developmental process in which a relatively unspecialized cell, e.g. embryonic or regenerative cell, acquires specialized structural and/or functional features that characterize a specific cell. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.
cell-cell signaling	Any process that mediates the transfer of information from one cell to another. This process includes signal transduction in the receiving cell and, where applicable, release of a ligand and any processes that actively facilitate its transport and presentation to the receiving cell. Examples include signaling via soluble ligands, via cell adhesion molecules and via gap junctions.
chondrocyte differentiation	The process in which a chondroblast acquires specialized structural and/or functional features of a chondrocyte. A chondrocyte is a polymorphic cell that forms cartilage.
embryonic digestive tract development	The process whose specific outcome is the progression of the gut over time, from its formation to the mature structure during embryonic development. The gut is the region of the digestive tract extending from the beginning of the intestines to the anus.
embryonic limb morphogenesis	The process, occurring in the embryo, by which the anatomical structures of the limb are generated and organized. A limb is an appendage of an animal used for locomotion or grasping.
embryonic skeletal system development	The process, occurring during the embryonic phase, whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure.
eye development	The process whose specific outcome is the progression of the eye over time, from its formation to the mature structure. The eye is the organ of sight.
fibroblast growth factor receptor signaling pathway	The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.
inner ear morphogenesis	The process in which the anatomical structures of the inner ear are generated and organized. The inner ear is the structure in vertebrates that contains the organs of balance and hearing. It consists of soft hollow sensory structures (the membranous labyrinth) containing fluid (endolymph) surrounded by fluid (perilymph) and encased in a bony cavity (the bony labyrinth). It consists of two chambers, the sacculus and utriculus, from which arise the cochlea and semicircular canals respectively.
lung development	The process whose specific outcome is the progression of the lung over time, from its formation to the mature structure. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax.
lung-associated mesenchyme development	The biological process whose specific outcome is the progression of a lung-associated mesenchyme from an initial condition to its mature state. This process begins with the formation of lung-associated mesenchyme and ends with the mature structure. Lung-associated mesenchyme is the tissue made up of loosely connected mesenchymal cells in the lung.
male gonad development	The process whose specific outcome is the progression of the male gonad over time, from its formation to the mature structure.
male sex determination	The specification of male sex of an individual organism.
mesenchymal cell proliferation	The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.
negative regulation of transcription by RNA polymerase II	Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II.
negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching	Any process that stops, prevents or reduces the frequency, rate or extent of vascular smooth muscle cell differentiation involved in phenotypic switching.
negative regulation of Wnt signaling pathway	Any process that stops, prevents, or reduces the frequency, rate or extent of the Wnt signaling pathway.
osteoblast differentiation	The process whereby a relatively unspecialized cell acquires the specialized features of an osteoblast, a mesodermal or neural crest cell that gives rise to bone.
positive regulation of activin receptor signaling pathway	Any process that activates or increases the frequency, rate or extent of the activity of any activin receptor signaling pathway.
positive regulation of canonical Wnt signaling pathway	Any process that increases the rate, frequency, or extent of the Wnt signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.
positive regulation of cardiac muscle cell proliferation	Any process that activates or increases the frequency, rate or extent of cardiac muscle cell proliferation.
positive regulation of cell division	Any process that activates or increases the frequency, rate or extent of cell division.
positive regulation of cell population proliferation	Any process that activates or increases the rate or extent of cell proliferation.
positive regulation of epithelial cell proliferation	Any process that activates or increases the rate or extent of epithelial cell proliferation.
positive regulation of gene expression	Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).
positive regulation of mesenchymal cell proliferation	The process of activating or increasing the rate or extent of mesenchymal cell proliferation. Mesenchymal cells are loosely organized embryonic cells.
positive regulation of protein phosphorylation	Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.
positive regulation of reproductive process	Any process that activates or increases the frequency, rate or extent of reproductive process.
positive regulation of smoothened signaling pathway	Any process that activates or increases the frequency, rate or extent of smoothened signaling.
positive regulation of stem cell proliferation	Any process that activates or increases the frequency, rate or extent of stem cell proliferation.
positive regulation of vascular associated smooth muscle cell migration	Any process that activates or increases the frequency, rate or extent of vascular associated smooth muscle cell migration.
positive regulation of vascular associated smooth muscle cell proliferation	Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell proliferation.
positive regulation of vascular endothelial growth factor receptor signaling pathway	Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity.
protein import into nucleus	The directed movement of a protein from the cytoplasm to the nucleus.
regulation of cell migration	Any process that modulates the frequency, rate or extent of cell migration.
regulation of timing of cell differentiation	The process controlling the activation and/or rate at which relatively unspecialized cells acquire specialized features. Any process that modulates the rate, frequency or extent of the XXX at a consistent predetermined time point during its development.
Sertoli cell proliferation	The multiplication or reproduction of Sertoli cells, resulting in the expansion of the Sertoli cell population. A Sertoli cell is a supporting cell projecting inward from the basement membrane of seminiferous tubules.
signal transduction	The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.
smoothened signaling pathway	The series of molecular signals generated as a consequence of activation of the transmembrane protein Smoothened.
stem cell proliferation	The multiplication or reproduction of stem cells, resulting in the expansion of a stem cell population. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.
substantia nigra development	The progression of the substantia nigra over time from its initial formation until its mature state. The substantia nigra is the layer of gray substance that separates the posterior parts of the cerebral peduncles (tegmentum mesencephali) from the anterior parts; it normally includes a posterior compact part with many pigmented cells (pars compacta) and an anterior reticular part whose cells contain little pigment (pars reticularis).
vascular endothelial growth factor receptor signaling pathway	The series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor (VEGFR) on the surface of the target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.

28 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
P48801	FGF3	Fibroblast growth factor 3	Gallus gallus (Chicken)	SS
O15520	FGF10	Fibroblast growth factor 10	Homo sapiens (Human)	SS
O43320	FGF16	Fibroblast growth factor 16	Homo sapiens (Human)	EV SS
P10767	FGF6	Fibroblast growth factor 6	Homo sapiens (Human)	SS
P11487	FGF3	Fibroblast growth factor 3	Homo sapiens (Human)	SS
Q92914	FGF11	Fibroblast growth factor 11	Homo sapiens (Human)	SS
Q9HCT0	FGF22	Fibroblast growth factor 22	Homo sapiens (Human)	SS
Q9NP95	FGF20	Fibroblast growth factor 20	Homo sapiens (Human)	SS
Q9NSA1	FGF21	Fibroblast growth factor 21	Homo sapiens (Human)	PR
P08620	FGF4	Fibroblast growth factor 4	Homo sapiens (Human)	PR
P21658	Fgf6	Fibroblast growth factor 6	Mus musculus (Mouse)	SS
Q9ESS2	Fgf22	Fibroblast growth factor 22	Mus musculus (Mouse)	SS
O35565	Fgf10	Fibroblast growth factor 10	Mus musculus (Mouse)	SS
Q9JJN1	Fgf21	Fibroblast growth factor 21	Mus musculus (Mouse)	PR
Q9ESL8	Fgf16	Fibroblast growth factor 16	Mus musculus (Mouse)	SS
Q9ESL9	Fgf20	Fibroblast growth factor 20	Mus musculus (Mouse)	SS
P11403	Fgf4	Fibroblast growth factor 4	Mus musculus (Mouse)	PR
P61329	Fgf12	Fibroblast growth factor 12	Mus musculus (Mouse)	PR
P05524	Fgf3	Fibroblast growth factor 3	Mus musculus (Mouse)	SS
P54130	Fgf9	Fibroblast growth factor 9	Mus musculus (Mouse)	SS
Q95L12	FGF9	Fibroblast growth factor 9	Sus scrofa (Pig)	SS
Q9EST9	Fgf20	Fibroblast growth factor 20	Rattus norvegicus (Rat)	SS
O54769	Fgf16	Fibroblast growth factor 16	Rattus norvegicus (Rat)	SS
P70492	Fgf10	Fibroblast growth factor 10	Rattus norvegicus (Rat)	SS
P36364	Fgf9	Fibroblast growth factor 9	Rattus norvegicus (Rat)	SS
Q6PBT8	fgf1	Putative fibroblast growth factor 1	Danio rerio (Zebrafish) (Brachydanio rerio)	SS
Q2HXK8	fgf16	Fibroblast growth factor 16	Danio rerio (Zebrafish) (Brachydanio rerio)	SS
P48802	fgf3	Fibroblast growth factor 3	Danio rerio (Zebrafish) (Brachydanio rerio)	SS

10	20	30	40	50	60
MAPLGEVGNY	FGVQDAVPFG	NVPVLPVDSP	VLLSDHLGQS	EAGGLPRGPA	VTDLDHLKGI
70	80	90	100	110	120
LRRRQLYCRT	GFHLEIFPNG	TIQGTRKDHS	RFGILEFISI	AVGLVSIRGV	DSGLYLGMNE
130	140	150	160	170	180
KGELYGSEKL	TQECVFREQF	EENWYNTYSS	NLYKHVDTGR	RYYVALNKDG	TPREGTRTKR
190	200
HQKFTHFLPR	PVDPDKVPEL	YKDILSQS